These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 16411066)

  • 1. Prolactinomas and pregnancy.
    Bronstein MD
    Pituitary; 2005; 8(1):31-8. PubMed ID: 16411066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactinomas in pregnancy: considerations before conception and during pregnancy.
    Glezer A; Bronstein MD
    Pituitary; 2020 Feb; 23(1):65-69. PubMed ID: 31792668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
    Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
    Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quinagolide and macroprolactinomas a progress?].
    Jaquet P
    Ann Endocrinol (Paris); 1997; 58(2):83-5. PubMed ID: 9239225
    [No Abstract]   [Full Text] [Related]  

  • 7. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
    Liu C; Tyrrell JB
    Pituitary; 2001 Aug; 4(3):179-85. PubMed ID: 12138991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature.
    Kuhn E; Weinreich AA; Biermasz NR; Jorgensen JOL; Chanson P
    Eur J Endocrinol; 2021 May; 185(1):99-108. PubMed ID: 33914699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term effects of pregnancy and bromocriptine treatment on prolactinomas--the value of radiologic studies.
    Badawy SZ; Marziale JC; Rosenbaum AE; Chang JK; Joy SE
    Early Pregnancy; 1997 Dec; 3(4):306-11. PubMed ID: 10086082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prolactinoma and pregnancy].
    Trifonov I
    Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
    [No Abstract]   [Full Text] [Related]  

  • 12. [Update on endocrinology: management of prolactinomas during pregnancy].
    Cecenarro LA; Estario P; Estario ME; Fux-Otta C
    Rev Fac Cien Med Univ Nac Cordoba; 2015; 72(3):170-4. PubMed ID: 26913801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
    Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
    Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
    Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
    Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactinoma in pregnancy.
    Molitch ME
    Best Pract Res Clin Endocrinol Metab; 2011 Dec; 25(6):885-96. PubMed ID: 22115164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
    Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current approach to treatments for prolactinomas.
    Tirosh A; Shimon I
    Minerva Endocrinol; 2016 Sep; 41(3):316-23. PubMed ID: 26399371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptor agonists for treating prolactinomas.
    Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
    Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine agonists and pituitary tumor shrinkage.
    Bevan JS; Webster J; Burke CW; Scanlon MF
    Endocr Rev; 1992 May; 13(2):220-40. PubMed ID: 1352243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical management of prolactinomas.
    Webster J
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):395-408. PubMed ID: 10909431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.